课题基金 / 基金详情

Double-Encapsulated mRNA Vaccine for COVID-19

Double-Encapsulated mRNA Vaccine for COVID-19
适用于 COVID-19 的双囊 mRNA 疫苗
批准号:
10611763
负责人:
TREVOR P. CASTOR
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-03 至 2025-02-28

项目摘要

项目成果

TREVOR P. CASTOR的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY COVID-19, the multiorgan disease caused by the novel coronavirus SARS-CoV-2, has become the most impactful healthcare, social, and economic crisis of our lifetime. SARS-CoV-2 is genetically related to the previous two coronaviruses that caused human outbreaks in the 21st century, SARS-CoV and MERS-CoV. Even though COVID-19 mortality is lower than the other two coronavirus diseases, the pandemic has impacted, by mid-April 2022, >500 million people worldwide, and caused >6 million deaths. Had the COVID-19 mortality been closer to those of SARS and MERS, the impact of the current pandemic would be incomparably more catastrophic. The need for cold storage, the requirement for boosters, and the potential for adverse allergic reactions, are major drawbacks of current COVID-19 vaccines. To address these shortcomings, we propose to generate a COVID-19 mRNA vaccine that is stable at room temperature, requires only one injection, thus being more practical to deploy nationally and globally during vaccination campaigns, and is less prone to cause hypersensitivity reactions. We plan to conduct this Proof-of- Concept study over a 24-month period with a multidisciplinary team of engineers, molecular virologists, and immunologists. Our overarching goal is to double nanoencapsulate the mRNA molecule that encodes the coronavirus Spike protein in phospholipid nanosomes and then into biodegradable polymer nanospheres to sustain mRNA release. We will characterize the antigenicity and integrity of the nanoencapsulated mRNA before and after nanoencapsulation and coating and determine the best process conditions that ensure stability at room temperature after lyophilization. We will also evaluate the safety, pharmacokinetics, and immunogenicity of the nanoencapsulated antigen and perform challenge studies in two animal models, in anticipation of subsequent clinical studies. Based on these studies, we will select the best nanoformulation for scale-up, more detailed characterization, establish potency and release specifications, and regulatory studies in Phase II.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Combination Therapeutic for Chronic Opioid Use Disorder Relapse
  • 批准号:
    10706844
  • 项目类别:
  • 资助金额:
    $33.57万
  • 财政年份:
    2023
  • 负责人:
    TREVOR P. CASTOR
  • 依托单位:
Development of cGMP Manufacturing Process for CBD
  • 批准号:
    8966448
  • 项目类别:
  • 资助金额:
    $74.21万
  • 财政年份:
    2015
  • 负责人:
    TREVOR P. CASTOR
  • 依托单位:
Development of SFS Fractionators
  • 批准号:
    8712743
  • 项目类别:
  • 资助金额:
    $22.49万
  • 财政年份:
    2014
  • 负责人:
    TREVOR P. CASTOR
  • 依托单位:
Development of cGMP Manufacturing Process for CBD
  • 批准号:
    8834719
  • 项目类别:
  • 资助金额:
    $22.48万
  • 财政年份:
    2014
  • 负责人:
    TREVOR P. CASTOR
  • 依托单位:
海外基金